» Subscribe Today!
More of what you want to know.
The Daily News
X

Forgot your password?
Skip Navigation LinksHome > Name & Property Search
Search results for 'Mitchell Steiner' | Search again
DeSoto Public Records:0
Shelby Public Records:79
Editorial:44
West Tennessee:0
Middle Tennessee:27
East Tennessee:0
Other:0

You must be a subscriber to see the full results of your search.

Please log in or subscribe below if you are not already a subscriber.

The Daily News subscribers get full access to more than 13 million names and addresses along with powerful search and download features. Get the business leads you need with powerful searches of public records and notices. Download listings into your spreadsheet or database.

Learn more about our services | Search again


Editorial Results (free)

1. Change on Tap for Many Local Public Companies -

Here’s a snapshot of recent news and developments at some of the publicly traded companies based in Memphis, reflecting the influence these companies have and the shadows they cast both in Memphis and beyond, in industries that range from bioscience to banking.

2. GTx Scientific Officer Resigns -

James Dalton, the chief scientific officer and vice president of Memphis-based GTx Inc., will resign effective Aug. 31 to become dean of the University of Michigan College of Pharmacy.

3. GTx Scientific Officer Resigns -

James Dalton, the chief scientific officer and vice president of Memphis-based GTx Inc., will resign effective Aug. 31 to become dean of the University of Michigan College of Pharmacy.

4. Steiner Resigns as CEO of GTx -

Dr. Mitchell Steiner has resigned effective Thursday from being CEO and vice chairman of GTx, the Memphis-based company he co-founded.

5. GTx Reports Net Loss, Improved Cash Position -

Memphis-based GTx reported a net loss of $7.8 million for the quarter ended Dec. 31 and an annual net loss of $42.1 million for 2013.

That compares to net losses of $10.7 million for the last quarter of 2012 and a net loss of $27.1 million for all of 2012.

6. GTx Reports Net Loss, Improved Cash Position -

Memphis-based GTx reported a net loss of $7.8 million for the quarter ended Dec. 31 and an annual net loss of $42.1 million for 2013.

That compares to net losses of $10.7 million for the last quarter of 2012 and a net loss of $27.1 million for all of 2012.

7. GTx Layoffs Show Drug Market’s Volatility -

The layoffs at Memphis-based GTx Inc., announced Tuesday, Oct. 1, came with the resignation of the drug manufacturing company’s chief financial officer and pay cuts for GTx’s top three leaders.

8. GTx Treatment Fails to Meet Goals -

Shares of GTx Inc. plunged on Monday after the drugmaker said an experimental treatment with the potential to prevent and treat muscle wasting in cancer patients failed to meet its goals in two late-stage clinical trials.

9. GTx Says Muscle Drug Misses Late-Stage Study Goals -

Shares of GTx Inc. plunged Monday after the drug developer said its potential treatment for muscle wasting in lung cancer patients fell short of some main goals in late-stage clinical testing.

10. GTx Posts Quarterly, Yearly Net Loss -

Memphis-based biopharmaceutical company GTx Inc. has reported net loss of $10.7 million for the fourth quarter ended Dec. 31 compared to a similar $10.7 million net loss in Q4 2011.

11. GTx Rebounds in Third Quarter -

Memphis-based biopharmaceutical company GTx Inc. on Thursday, Nov. 8, reported net income of $7.4 million for the third quarter, fueled primarily from $18.8 million in net proceeds from the sale in early October of Fareston, a breast treatment medication.

12. Entrepreneurial Ecosystem -

Maybe you’re a startup founder who wants to rub shoulders with your peers, pitch investors in the hope of landing venture capital and talk to a lawyer about drawing up paperwork.

Maybe you’re a veteran researcher who’s got a side project that looks like it could turn into something big. Or maybe you’ve got little more than an idea on the back of a napkin.

13. GTx Narrows Q2 Loss -

GTx Inc. Wednesday, Aug. 8, reported a net loss of $10.4 million for the second quarter, compared to a net loss of $10.7 million for the same period in 2011.

14. GTx Narrows Q2 Loss -

GTx Inc. Wednesday, Aug. 8, reported a net loss of $10.4 million for the second quarter, compared to a net loss of $10.7 million for the same period in 2011.

15. GTx Reports $11.1 Million Q1 Net Income Loss -

Memphis-based biopharmaceutical company GTx Inc. on Tuesday, May 8, reported an $11.1 million net loss for the first quarter, compared to a net loss of $2.6 million for the same period in 2011.

16. Steiner, GTx Inc. Prepare For Next Step of Journey -

Dr. Mitchell Steiner recently returned from a trip to Eastern Europe, where he visited hospitals participating in international clinical trials for the drug enobosarm, which is being developed by his Memphis-based public biopharmaceutical company GTx Inc.

17. Performance Of Memphis Public Cos. Varies Widely -

Memphis is home to several publicly traded companies that have made an indelible mark on industries ranging from transportation to finance and manufacturing.

Here’s a snapshot of how those companies are faring at the moment. (For a detailed look at AutoZone, see related story, "The Fast Lane.")

18. FDA Places Hold on GTx Study as Company Reports Earnings Drop -

Memphis-based pharmaceutical company GTx Inc. on Tuesday, Feb. 21, announced that the U.S. Food and Drug Administration had placed a clinical hold on the company’s Phase II clinical studies for Capesaris.

19. FDA Places Hold on GTx Study as Company Reports Earnings Drop -

Memphis-based pharmaceutical company GTx Inc. on Tuesday, Feb. 21, announced that the U.S. Food and Drug Administration had placed a clinical hold on the company’s Phase II clinical studies for Capesaris.

20. GTx Posts $9.3M Q3 Loss -

Memphis-based GTx Inc. reported Friday, Nov. 4, a $9.3 million loss for the third quarter as the company ramped up research and development on two drugs in clinical development programs.

21. GTx Posts $9.3M Q3 Loss -

Memphis-based GTx Inc. reported Friday, Nov. 4, a $9.3 million loss for the third quarter as the company ramped up research and development on two drugs in clinical development programs.

22. GTx, Ipsen Terminate Drug Collaboration -

Memphis biopharmaceutical startup GTx Inc. said Wednesday it and French-based pharmaceutical giant Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

23. GTx, Ipsen Terminate Drug Collaboration -

Memphis biopharmaceutical startup GTx Inc. said Wednesday it and French-based pharmaceutical giant Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

24. GTx Reports Q4 Loss, but 2010 Profit -

Memphis-based biopharmaceutical company GTx Inc. Thursday reported a $7.5 million net loss in the fourth quarter, but posted a $15.3 million profit for the full-year, ended Dec. 31.

25. GTx Reports Q4 Loss, But 2010 Profit -

Memphis-based biopharmaceutical company GTx Inc. Thursday reported a $7.5 million net loss in the fourth quarter, but posted a $15.3 million profit for the full-year, ended Dec. 31.

26. GTx Announces Positive News for Drug -

GTx has announced that tests of a drug it is developing show its “potential as a new hormonal treatment for advanced prostate cancer,” according to Mitchell Steiner, CEO of the Memphis-based biopharmaceutical company.

27. Study: Drug Helped Women Without Side Effects -

Ostarine, a drug that Memphis-based GTx Inc. is developing for cancer wasting, was noted to have improved body mass and leg strength in the first study conducted exclusively on postmenopausal women.

28. GTx Reports $44.3M Net Income -

GTx Inc. is pressing ahead with the development of a drug for muscle wasting in cancer patients after ending its partnership with Merck.

29. UPDATE: GTx Announces Lay-Offs -

GTx said today it laid off 28 percent of its work force, a reduction that is a direct result of the U.S. Food and Drug Administration’s decision on Oct. 30 to not grant approval of a drug the Memphis-based company is developing.

30. GTx Releases Earnings Report, Touts Other Drugs -

What a difference a week makes.

Seven days after explaining why the U.S. Food and Drug Administration did not approve its first drug product, Memphis-based GTx Inc. hosted a second conference call Monday when it reported earnings for the third quarter.

31. GTx Receives ‘Complete Surprise’ From Food and Drug Admin -

The stock of Memphis-based GTx Inc. plunged 45 percent Monday morning after the company explained why the U.S. Food and Drug Administration did not grant approval for its drug to prevent bone fractures in men with prostate cancer who are undergoing hormone deprivation treatment.

32. GTx Prepares for Market Launch -

GTx Inc. is exploring whether to hire its own sales force or partner with another entity as it prepares to transition from a company almost exclusively involved in research and development to one with its own products.

33. GTx Starts Trial For New Drug -

GTx Inc. reported Monday it has initiated Phase 1 clinical trial of GTx-758, another drug to treat men with advanced prostate cancer.

34. GTx Addresses Change On Drug Label -

Memphis-based GTx Inc. discussed with investors on Friday the label change for Fareston (toremifene citrate) 60 mg by the European Medicines Agency.

35. GTx, UT Foundation Reach Agreement -

GTx Inc. and the University of Tennessee Research Foundation have reached an agreement in a dispute over income from a drug therapy, the company said in a filing with the Securities and Exchange Commission.

36. GTx Submits FDA Application For New Drug -

Memphis-based GTx announced Tuesday morning that it had submitted a new drug application with the U.S. Food and Drug Administration for the prevention of bone fractures in men undergoing drug therapy for prostate cancer.

37. UTHSC Professors Receive Patents -

Sixteen professors at the University of Tennessee Health Science Center who turned laboratory experiments into practical applications have received patents for innovations in medicine.

Besides the potential for better ways to diagnose the sick and injured, these innovations could provide a revenue stream for UTHSC.

38. Former Mud Island Tour Guide Directs Future of Memphis Medical Center -

As a history major at then-Memphis State University in the early 1990s, Beth Flanagan worked as a tour guide at Mud Island River Park. She loved telling visitors about the rich history of the island and of Downtown Memphis.

39. Morton Joins GTxAs Chief Medical Officer -      Dr. Ronald A. Morton Jr. has been appointed chief medical officer at GTx Inc.
     GTx is a Memphis-based biopharmaceutical company.
     Morton previously worke

40. GTx Inc. to be ListedOn the NASDAQ Index - Memphis-based biopharmaceutical company GTx Inc. will be added to the NASDAQ Biotechnology Index by next Monday.

The Index contains securities of companies listed by the Industry Classification Benchmark as either biotechnology or pharmaceut

41. Archived Article: Events - The Kiwanis Club of Memphis meets at noon Wednesday in the Venetian Room at the Peabody, 149 Union Ave

The Kiwanis Club of Memphis meets at noon today in the Venetian Room at The Peabody, 149 Union Ave. Dr. Mitchell Steiner, founder and chief exe...

42. Archived Article: Comm Focus1 - Early intervention Early intervention Raines-Cox Urology Institute offers free prostate cancer screenings The Raines-Cox Urology Institute, new non-profit medical research and treatment organization, is offering free prostate cancer screenings as th...

43. Archived Article: Memos - Buckeye Board Elects New Officer Jeffery T. Cook has been elected vice president, product development-new fibers for Buckeye Technologies Inc. Cook is a graduate of Vanderbilt University. Melissa Smith has joined Chandler, Ehrlich & Co. as media...

44. Archived Article: Standout (steiner) Lj - lj 10/5 cates Conquering a killer Dr. Mitchell Steiner set to begin clinical trials for innovative prostate cancer treatment By LAURIE JOHNSON The Daily News A University of Tennessee-Memphis professor and oncology specialist is poised to begin clin...